Training the Immune System to Recognize Cancer Cells

Chief Executive Officer, Chairman, and Director

Portage Biotech, Inc.

Jul 8, 2021PTV-07-21-CL-001-838

Ian Walters, CEO of Portage Biotech, discusses the challenges facing immuno-oncology and the unique approach the company has taken.

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.

Reach Our Team

Subscribe for the newsletter

Subscribe for the Newsletter

Mobile Navigation

Training the Immune System to Recognize Cancer Cells

Related Content

Oncology

Harnessing Macrophage Biology to Overcome Tumor Immune Evasion

Roy Maute, Ph.D.

Pheast Therapeutics

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac

Basket Trials

Basket Trials and the Future of Rare Cancer Research

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

Research Collab

10x Genomics and Cleveland Clinic Collaborate in Diagnostic Applications of Single Cell and Spatial Technologies in Bladder Cancer

10x Genomics

ADCs

Re-Engineering ADCs for Autoimmune and Inflammatory Disease

David Alvaro, Ph.D.

Pharma's Almanac

Ovarian Cancer

Oncolytic Viruses at a Turning Point: Advancing Olvi-Vec for Advanced Ovarian Cancer

David Alvaro, Ph.D.; Jason Litten, M.D.

Pharma's Almanac

Ovarian Cancer

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Ernexa Therapeutics

Nobel Prize

Peacekeepers of Immunity: The Nobel-Winning Discovery That Redefined Immunity

David Alvaro, Ph.D.

Pharma's Almanac

Inducement Grants

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals

Collaboration

TegMine Therapeutics Enters Collaboration with Boehringer Ingelheim to Advance Novel 2-Factor Antibody System for Cancer

Tegmine Therapeutics

Related Content

Oncology

Harnessing Macrophage Biology to Overcome Tumor Immune Evasion

Roy Maute, Ph.D.

Pheast Therapeutics

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac

Basket Trials

Basket Trials and the Future of Rare Cancer Research

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

Research Collab

10x Genomics and Cleveland Clinic Collaborate in Diagnostic Applications of Single Cell and Spatial Technologies in Bladder Cancer

10x Genomics

ADCs

Re-Engineering ADCs for Autoimmune and Inflammatory Disease

David Alvaro, Ph.D.

Pharma's Almanac

Ovarian Cancer

Oncolytic Viruses at a Turning Point: Advancing Olvi-Vec for Advanced Ovarian Cancer

David Alvaro, Ph.D.; Jason Litten, M.D.

Pharma's Almanac